Clinical Trials Logo

Advanced Malignant Solid Tumors clinical trials

View clinical trials related to Advanced Malignant Solid Tumors.

Filter by:

NCT ID: NCT00768469 Completed - Clinical trials for Advanced Malignant Solid Tumors

Study Evaluating Safety And Tolerability, Solid Tumor

Start date: October 2008
Phase: Phase 1
Study type: Interventional

This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.

NCT ID: NCT00728468 Completed - Clinical trials for Advanced Malignant Solid Tumors

A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients

Start date: September 2008
Phase: Phase 1
Study type: Interventional

Research in test tubes suggests that may affect cytochrome P450 2D6 (CYP2D6), an important enzyme that is responsible for eliminating many drugs that cancer patients need to take, including dextromethorphan. The purpose of this study is to test the impact of PF-00299804 on the activity of CYP2D6, and how the human body handles dextromethorphan.

NCT ID: NCT00706030 Completed - Breast Cancer Clinical Trials

Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Start date: April 29, 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to identify the highest tolerable dose of neratinib (HKI-272) in combination with vinorelbine and to assess the safety of the combination of the two drugs as well as to obtain preliminary information on whether the combination of the two drugs has any effect on solid tumors. The study will be conducted in two parts. In the first part, testing will be done on up to 12 subjects to determine the highest tolerable dose of HKI-272 and vinorelbine in patients with advanced solid tumors. In the second part of the study, approximately 60 additional subjects with metastatic ErbB-2-positive breast cancer, with no prior exposure to lapatinib, are planned to be added to better define the tolerability and preliminary activity of HKI-272 in combination with vinorelbine. Up to 20 additional subjects with ErbB-2-positive breast cancer with prior lapatinib exposure are also planned to be enrolled in part 2 for exploratory analyses.

NCT ID: NCT00445458 Completed - Breast Neoplasms Clinical Trials

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Start date: September 11, 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to learn whether it is safe and effective to administer HKI-272 (neratinib) in combination with paclitaxel in patients with breast cancer.